Drug-Induced Hypouricemia.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
accepted:
03
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
aheadofprint
Résumé
Hypouricemia is defined as a serum uric acid concentration of ≤ 2.0 mg/dL or 119 μmol/L. Hypouricemia may occur secondarily to a number of underlying conditions, including severe hepatocellular disease, neoplasia, defective renal tubular reabsorption of uric acid, inherited metabolic defect in purine metabolism, and drugs. Medications are an important cause of hypouricemia. They can cause hypouricemia by a variety of mechanisms. Drug-induced hypouricemia mostly occurs as overtreatment of hyperuricemia by urate-lowering therapies including xanthine oxidase inhibitors, uricosuric agents and uricases. Drugs not used in the treatment of gout may also lead to a decrease of uric acid levels. In this literature review, medications leading to hypouricemia are summarized with regard to their mechanism of action and clinical significance.
Identifiants
pubmed: 39289314
doi: 10.1007/s40264-024-01485-7
pii: 10.1007/s40264-024-01485-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Praetorius E, Kirk JE. Hypouricemia: with evidence for tubular elimination of uric acid. J Lab Clin Med. 1950;35:865–8.
pubmed: 15422225
Son CN, Kim JM, Kim SH, Cho SK, Choi CB, Sung YK, et al. Prevalence and possible causes of hypouricemia at a tertiary care hospital. Korean J Intern Med. 2016;31:971–6.
pubmed: 26956409
pmcid: 5016282
Ogino K, Hisatome I, Saitoh M, Miyamoto J, Ishiko R, Hasegawa J, et al. Clinical significance of hypouricemia in hospitalized patients. J Med. 1991;22:76–82.
pubmed: 1895016
Zhou Z, Ma L, Zhou J, Song Z, Zhang J, Wang K, et al. Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: a case report with literature review. BMC Med Genet. 2018;19:142.
pubmed: 30097038
pmcid: 6086067
Iwai N, Mino Y, Hosoyamada M, Tago N, Kokubo Y, Endou H. A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int. 2004;66:935–44.
pubmed: 15327384
Lee JH, Choi HJ, Lee BH, Kang HK, Chin HJ, Yoon HJ, et al. Prevalence of hypouricemia and SLC22A12 mutations in healthy Korean subjects. Nephrology (Carlton). 2008;13:661–6.
pubmed: 19019168
Zhou Z, Wang K, Zhou J, Wang C, Li X, Cui L, et al. Amplicon targeted resequencing for SLC2A9 and SLC22A12 identified novel mutations in hypouricemia subjects. Mol Genet Genomic Med. 2019;7: e00722.
pubmed: 31131560
pmcid: 6625124
Stiburkova B, Gabrikova D, Čepek P, Šimek P, Kristian P, Cordoba-Lanus E, et al. Prevalence of URAT1 allelic variants in the Roma population. Nucleosides Nucleotides Nucleic Acids. 2016;35:529–35.
pubmed: 27906637
Ichida K, Amaya Y, Okamoto K, Nishino T. Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans. Int J Mol Sci. 2012;13:15475–95.
pubmed: 23203137
pmcid: 3509653
Mraz M, Hurba O, Bartl J, Dolezel Z, Marinaki A, Fairbanks L, et al. Modern diagnostic approach to hereditary xanthinuria. Urolithiasis. 2015;43:61–7.
pubmed: 25370766
Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017;56:679–88.
pubmed: 27498351
Tátrai P, Erdő F, Dörnyei G, Krajcsi P. Modulation of urate transport by drugs. Pharmaceutics. 2021;13:899.
pubmed: 34204277
pmcid: 8235739
Ramsdell CM, Kelley WN. The clinical significance of hypouricemia. Ann Intern Med. 1973;78:239–42.
pubmed: 4683752
Bairaktari ET, Kakafika AI, Pritsivelis N, Hatzidimou KG, Tsianos EV, Seferiadis KI, et al. Hypouricemia in individuals admitted to an inpatient hospital-based facility. Am J Kidney Dis. 2003;41:1225–32.
pubmed: 12776275
Godin M. Hypouricemia (author’s transl). Nouv Presse Med. 1979;8:4099–103.
pubmed: 530826
Makinouchi R, Koyama T, Machida S, Imai N. Hypouricemia in the emergency department: A retrospective, single-center study. Health Sci Rep. 2023;6: e1467.
pubmed: 37575203
pmcid: 10412855
Mazza A, Zamboni S, Rizzato E, Pessina AC, Tikhonoff V, Schiavon L, et al. Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL). Acta Diabetol. 2007;44:99–105.
pubmed: 17721747
Kang E, Hwang S-S, Kim DK, Oh KH, Joo KW, Kim YS, et al. Sex-specific relationship of serum uric acid with all-cause mortality in adults with normal kidney function: an observational study. J Rheumatol. 2017;44:380–7.
pubmed: 28089980
Kuwabara M, Hisatome I, Niwa K, Bjornstad P, Roncal-Jimenez CA, Andres-Hernando A, et al. The optimal range of serum uric acid for cardiometabolic diseases: a 5-year japanese cohort study. J Clin Med. 2020;9:942.
pubmed: 32235468
pmcid: 7231289
Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DC, Taiwan Geriatric Kidney Disease (TGKD) Research Group. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment. J Am Heart Assoc. 2018;7:e007523.
pubmed: 29440009
pmcid: 5850189
Cho SK, Chang Y, Kim I, Ryu S. U-shaped association between serum uric acid level and risk of mortality: a cohort study. Arthritis Rheumatol. 2018;70:1122–32.
pubmed: 29694719
Miake J, Hisatome I, Tomita K, Isoyama T, Sugihara S, Kuwabara M, et al. Impact of hyper- and hypo-uricemia on kidney function. Biomedicines. 2023;11:1258.
pubmed: 37238929
pmcid: 10215381
Otani N, Ouchi M, Mizuta E, Morita A, Fujita T, Anzai N, et al. Dysuricemia—a new concept encompassing hyperuricemia and hypouricemia. Biomedicines. 2023;11:1255.
pubmed: 37238926
pmcid: 10215565
Dissanayake LV, Spires DR, Palygin O, Staruschenko A. Effects of uric acid dysregulation on the kidney. Am J Physiol Renal Physiol. 2020;318:F1252–7.
pubmed: 32223309
pmcid: 7294331
Wakasugi M, Kazama JJ, Narita I, Konta T, Fujimoto S, Iseki K, et al. Association between hypouricemia and reduced kidney function: a cross-sectional population-based study in Japan. Am J Nephrol. 2015;41:138–46.
pubmed: 25790961
Ueda H, Inoue K, Seki R, Nemoto Y, Terawaki H. Lower range of serum uric acid level increases risk of rapid decline of kidney function in young and middLe-aged adults: the Yuport Medical Checkup Center Study. Clin Exp Nephrol. 2023;27:435–44.
pubmed: 36773175
pmcid: 10104940
Kasahara M, Kuwabara Y, Moriyama T, Tanabe K, Satoh-Asahara N, Katsuya T, et al. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial. Clin Exp Nephrol. 2020;24:235–41.
pubmed: 31729647
Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10:271–83.
pubmed: 24614592
Gao B, Bao Y, Meng M, Yu L, Lu Y, Sa R, et al. Association of serum uric acid with risk of stroke in US adults: a cross-sectional study from NHANES 1999–2020. J Stroke Cerebrovasc Dis. 2023;32: 107206.
pubmed: 37276787
Park JH, Jo YI, Lee JH. Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med. 2020;35:1291–304.
pubmed: 32872730
pmcid: 7652664
RundLes RW, Wyngaarden JB. Drugs and uric acid. Annu Rev Pharmacol. 1969;9:345–62.
pubmed: 4953095
Kelley WN. Effects of drugs on uric acid in man. Annu Rev Pharmacol. 1975;15:327–50.
pubmed: 1096789
Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20:983–92.
pubmed: 27010159
Kelley WN. Hypouricemia. Arthritis Rheum. 1975;18:731–7.
pubmed: 1239291
Otani N, Ouchi M, Kudo H, Tsuruoka S, Hisatome I, Anzai N. Recent approaches to gout drug discovery: an update. Expert Opin Drug Discov. 2020;15:943–54.
pubmed: 32329387
El-Sheikh AAK, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol. 2008;155:1066–75.
pubmed: 18724382
pmcid: 2597258
Alghamdi YS, Soliman MM, Nassan MA. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study. BMC Pharmacol Toxicol. 2020;21:10.
pubmed: 32041665
pmcid: 7011467
Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.
pubmed: 21906289
pmcid: 3189112
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744–60.
pubmed: 32391934
pmcid: 10563586
Hasikova L, Bartl J, Stiburkova B. Urinary oxypurinol is a useful tool to assess adherence to allopurinol in clinical practice. Rheumatology (Oxford). 2024;63:e174–6.
pubmed: 38197578
Wallace MC, Roberts RL, Nanavati P, Miner JN, Dalbeth N, Topless R, et al. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology (Oxford). 2018;57:656–60.
pubmed: 29342288
Vickneson K, George J. Xanthine oxidoreductase inhibitors. Handb Exp Pharmacol. 2021;264:205–28.
pubmed: 32789757
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396:1745–57.
pubmed: 33181081
Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H. Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations. Front Pharmacol. 2016;7:518.
pubmed: 28082903
pmcid: 5187494
Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68:2035–43.
pubmed: 26894653
Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol. 2019;71:143–53.
pubmed: 30073793
Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2016;41:298–305.
pubmed: 27079434
Nagaoka Y, Tanaka Y, Yoshimoto H, Suzuki R, Ryu K, Ueda M, et al. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis. Hemodial Int. 2018;22:388–93.
pubmed: 29227568
Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12:3167–81.
pubmed: 32774692
pmcid: 7407685
Terkeltaub R. Emerging uricosurics for gout. Expert Rev Clin Pharmacol. 2017;10:247–9.
pubmed: 27937050
Li X, Liu J, Ma L, Fu P. Pharmacological urate-lowering approaches in chronic kidney disease. Eur J Med Chem. 2019;166:186–96.
pubmed: 30769179
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447–52.
pubmed: 12024214
Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol. 2011; 29–104.
Hsyu PH, Gisclon LG, Hui AC, Giacomini KM. Interactions of organic anions with the organic cation transporter in renal BBMV. Am J Physiol. 1988;254:F56-61.
pubmed: 2962517
Pfister B, Imhof P, Wirz H. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol. 1978;13:263–5.
pubmed: 668783
Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol. 1962;1966(4):91–142.
Seegmiller JE, Grayzel AI. Use of the newer uricosuric agents in the management of gout. JAMA. 1960;173:1076–80.
pubmed: 14444480
Jain AK, Ryan JR, McMahon FG, Noveck RJ. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum. 1974;17:149–57.
pubmed: 4814978
Heel RC, Brogden RN, Speight TM, Avery GS. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs. 1977;14:349–66.
pubmed: 338280
Reinders MK, van Roon EN, Houtman PM, Brouwers JRBJ, Jansen TLTA. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26:1459–65.
pubmed: 17308859
Liu D, Zhou B, Li Z, Zhang Z, Dai X, Ji Z, et al. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. Clin Rheumatol. 2022;41:2121–8.
pubmed: 35229198
Chou HW, Chiu HT, Tsai CW, Ting IW, Yeh HC, Huang HC, et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018;33:1620–7.
pubmed: 29165620
Shahid H, Singh JA. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24:1013–30.
pubmed: 26073200
Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018;57:i42–6.
pubmed: 29272511
Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214.
pubmed: 27716403
pmcid: 5048659
Toyoda Y, Kawamura Y, Nakayama A, Morimoto K, Shimizu S, Tanahashi Y, et al. OAT10/SLC22A13 acts as a renal urate re-absorber: clinico-genetic and functional analyses with pharmacological impacts. Front Pharmacol. 2022;13: 842717.
pubmed: 35462902
pmcid: 9019507
Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, AdLer S, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56:2170–8.
pubmed: 29029210
Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:80–91.
pubmed: 31875931
Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf. 2017;8:379–88.
pubmed: 29204266
pmcid: 5703101
Stamp LK, O’Donnell JL, Chapman PT. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J. 2007;37:258–66.
pubmed: 17388867
Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK. Review of urate-lowering therapeutics: from the past to the future. Front Pharmacol. 2022;13: 925219.
pubmed: 36081938
pmcid: 9445164
Pineda C, Soto-Fajardo C, Mendoza J, Gutiérrez J, Sandoval H. Hypouricemia: what the practicing rheumatologist should know about this condition. Clin Rheumatol. 2020;39:135–47.
pubmed: 31650389
Smink PA, Bakker SJL, Laverman GD, Berl T, Cooper ME, de Zeeuw D, et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens. 2012;30:1022–8.
pubmed: 22388234
Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol. 2000;27:2232–6.
pubmed: 10990239
Katsiki N, Tsioufis K, Ural D, Volpe M. Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: an “old dog playing good tricks.” J Clin Hypertens (Greenwich). 2018;20:1153–9.
pubmed: 29907995
Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–9.
pubmed: 14871425
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving H-H, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2–7.
pubmed: 21632472
Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320:211–7.
pubmed: 17043154
Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008;25:639–46.
pubmed: 17674156
Sutton Burke EM, Kelly TC, Shoales LA, Nagel AK. Angiotensin receptor blockers effect on serum uric acid—a class effect? J Pharm Pract. 2020;33:874–81.
pubmed: 31390929
Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci. 2010;114:115–8.
pubmed: 20736511
Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens. 2006;20:45–50.
pubmed: 16281062
Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17:397–414.
pubmed: 15107595
Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther. 1987;1:29–38.
pubmed: 3154308
Malini PL, Strocchi E, Ambrosioni E, Magnani B. Long-term antihypertensive, metabolic and cellular effects of enalapril. J Hypertens Suppl. 1984;2:S101-105.
pubmed: 6100870
Renke M, Tylicki L, Rutkowski P, Rutkowski B. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scand J Urol Nephrol. 2004;38:427–33.
pubmed: 15764256
Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton). 2011;16:156–62.
pubmed: 21272127
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005;11:4161–75.
pubmed: 16375738
Buscemi S, Buscemi C, Borzì AM, Cosentino L, Rosafio G, Randazzo C, et al. Metabolic and cardiovascular effects of switching thiazides to amlodipine in hypertensive patients with and without type 2 diabetes (the diuretics and diabetes control study). Metab Syndr Relat Disord. 2020;18:110–8.
pubmed: 31976814
Juraschek SP, Simpson LM, Davis BR, Shmerling RH, Beach JL, Ishak A, et al. The effects of antihypertensive class on gout in older adults: secondary analysis of the antihypertensive and lipid-lowering treatment to prevent heart attack trial. J Hypertens. 2020;38:954–60.
pubmed: 31977576
pmcid: 7244334
Zhang D, Huang Q-F, Sheng C-S, Li Y, Wang J-G. Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers. Blood Press. 2021;30:395–402.
pubmed: 34714194
Rubio-Guerra AF, Garro-Almendaro AK, Elizalde-Barrera CI, Suarez-Cuenca JA, Duran-Salgado MB. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis. 2017;11:57–62.
pubmed: 27932570
Hori T, Ouchi M, Otani N, Nohara M, Morita A, Otsuka Y, et al. The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate under-excretion animal models. J Pharmacol Sci. 2018;136:196–202.
pubmed: 29656005
Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y, et al. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb. 2004;11:335–40.
pubmed: 15644587
Waldman B, Ansquer J-C, Sullivan DR, Jenkins AJ, McGill N, Buizen L, et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018;6:310–8.
pubmed: 29496472
Zhang J, Ji X, Dong Z, Lu J, Zhao Y, Li R, et al. Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. Endocr J. 2021;68:829–37.
pubmed: 33731500
Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43:522–31.
pubmed: 23480615
Ristic B, Sikder MOF, Bhutia YD, Ganapathy V. Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. Asian J Pharm Sci. 2020;15:173–80.
pubmed: 32373197
Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. Sci Rep. 2018;8:16767.
pubmed: 30425304
pmcid: 6233215
Cao JY, Waldman B, O’Connell R, Sullivan DR, Scott RS, Aryal N, et al. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020;22:1388–96.
pubmed: 32243036
Derosa G, Maffioli P, Reiner Ž, Simental-Mendía LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76:947–56.
pubmed: 27260336
Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148:635–40.
pubmed: 15459594
Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004;55:53–62.
pubmed: 14759090
Balaguer C, Peralta A, Ríos Á, Iglesias A, Valera JL, Noguera A, et al. Effects of simvastatin in chronic obstructive pulmonary disease: results of a pilot, randomized, placebo-controlled clinical trial. Contemp Clin Trials Commun. 2016;2:91–6.
pubmed: 29736450
pmcid: 5935853
Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol. 2003;43:825–30.
pubmed: 12953339
Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacol Ther. 2012;136:106–30.
pubmed: 22841915
Pascart T, Latourte A, Flipo R-M, Chalès G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020;87:395–404.
pubmed: 32422338
Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors. Adv Exp Med Biol. 2021;1307:213–30.
pubmed: 32006266
Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181–9.
pubmed: 23748519
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142:1028–39.
pubmed: 32410463
pmcid: 7521417
Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43:3435–46.
pubmed: 35788657
pmcid: 9492270
Banerjee M, Pal R, Maisnam I, Chowdhury S, Mukhopadhyay S. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: a meta-analysis and meta-regression of randomized controlled trials. Diabetes Obes Metab. 2023;25:2697–703.
pubmed: 37334516
Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21:1291–8.
pubmed: 30762288
Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458–62.
pubmed: 28846182
Mori D, Kobayashi M, Wada M, Tokuchi M, Misegawa S, Saito R, et al. Effect of dapagliflozin on serum uric acid levels in patients with advanced chronic kidney disease. Intern Med. 2024;63:353–7.
pubmed: 37344435
Lu YH, Chang YP, Li T, Han F, Li CJ, Li XY, et al. Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK/AKT/CREB signaling pathway in type 2 diabetic mice. Int J Biol Sci. 2020;16:529–42.
pubmed: 32015688
pmcid: 6990905
Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney Function. Clin J Am Soc Nephrol. 2022;17:663–71.
pubmed: 35322793
pmcid: 9269569
Stamp LK, O’Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthritis Rheum. 2013;65:1636–42.
pubmed: 23681955
Tiitinen S, Nissilä M, Ruutsalo HM, Isomäki H. Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid. Clin Rheumatol. 1983;2:233–6.
pubmed: 6678696
Bou-Salah L, Benarous K, Linani A, Rabhi F, Chaib K, Chine I, et al. Anti-inflammatory drugs as new inhibitors to xanthine oxidase: In vitro and in silico approach. Mol Cell Probes. 2021;58: 101733.
pubmed: 33957269
Liu C, Zhen Y, Zhao Q, Zhai JL, Liu K, Zhang JX. Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance. Can J Physiol Pharmacol. 2016;94:797–800.
pubmed: 27144905
Liu C, Zhao Q, Zhen Y, Gao Y, Tian L, Wang L, et al. Prednisone in uric acid lowering in symptomatic heart failure patients with hyperuricemia (PUSH-PATH) study. Can J Cardiol. 2013;29:1048–54.
pubmed: 23395281
Meng H, Liu G, Zhai J, Zhen Y, Zhao Q, Zheng M, et al. Prednisone in uric acid lowering in symptomatic heart failure patients with hyperuricemia—the PUSH-PATH3 study. J Rheumatol. 2015;42:866–9.
pubmed: 25774058
Arida D, Silva L, Skare TL. The hypouricemiant effect of leflunomide. Joint Bone Spine. 2014;81:273–4.
pubmed: 24289959
Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39:655–65.
pubmed: 10888712
Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handLing of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol. 2003;9:215–8.
pubmed: 17041461
Choe JY, Kim SK. Association between serum uric acid and inflammation in rheumatoid arthritis: perspective on lowering serum uric acid of leflunomide. Clin Chim Acta. 2015;438:29–34.
pubmed: 25108207
Kis E, Nagy T, Jani M, Molnár E, Jánossy J, Ujhellyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009;68:1201–7.
pubmed: 18397960
Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305–9.
pubmed: 19592386
Posadzy-Malaczynska A, Rajpold K, Woznicka-Leskiewicz L, Marcinkowska J. Reversal of an unfavorable effect of hydrochlorothiazide compared to angiotensin converting enzyme inhibitor on serum uric acid and oxypurine levels by estrogen-progestin therapy in hypertensive postmenopausal women. Curr Med Res Opin. 2019;35:1687–97.
pubmed: 31033362
Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, Morcillo S, Rojo-Martínez G, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab. 2008;93:2230–3.
pubmed: 18349066
Takiue Y, Hosoyamada M, Kimura M, Saito H. The effect of female hormones upon urate transport systems in the mouse kidney. Nucleosides Nucleotides Nucleic Acids. 2011;30:113–9.
pubmed: 21360409
Taniguchi K, Tamura Y, Kumagai T, Shibata S, Uchida S. Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH. Clin Exp Nephrol. 2016;20:845–52.
pubmed: 26935049
Kim GH, Jun JB. Altered serum uric acid levels in kidney disorders. Life (Basel). 2022;12:1891.
pubmed: 36431026
pmcid: 9692609
Wang G, Zuo T, Li R. The mechanism of Arhalofenate in alleviating hyperuricemia-activating PPARγ thereby reducing caspase-1 activity. Drug Dev Res. 2020;81:859–66.
pubmed: 32506648
Shalev A, Hermesh H, Munitz H. The hypouricemic effect of chlorprothixene. Clin Pharmacol Ther. 1987;42:562–6.
pubmed: 3315391
Toyota T, Oikawa S, Abe R, Sano R, Suzuki N, Hisamichi S, et al. Effect of cilostazol on lipid, uric acid and glucose metabolism in patients with impaired glucose tolerance or type 2 diabetes mellitus: a double-blind, placebo-controlled study. Clin Drug Investig. 2001;21:325–35.
Hansen OE, Holten C. Uricosuric effect of dicoumarol. Lancet. 1958;1:1047–8.
pubmed: 13540248
Ramsdell CM, Postlethwaite AE, Kelley WN. Uricosuric effect of glyceryl guaiacolate. J Rheumatol. 1974;1:114–6.
pubmed: 4617771
Noveck RJ, Wang Z, Forsthoefel A, et al. Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout [absract]. Arthritis Rheum. 2012;64:S356.
Warrell RP, Muindi J, Stevens YW, Isaacs M, Young CW. Induction of profound hypouricemia by a non-sedating thiobarbiturate. Metabolism. 1989;38:550–4.
pubmed: 2725294
Zumoff B. The hypouricemic effect of o, p’-DDD. Am J Med Sci. 1979;278:145–7.
pubmed: 517567
Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med. 1971;74:845–52.
pubmed: 5580635
Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005;52:290–5.
pubmed: 15641045
Fujimura A, Ebihara A, Hino N, Koike Y. Effects of traxanox sodium on blood pressure and serum uric acid in hypertensive patients: a preliminary study. J Clin Pharmacol. 1989;29:327–30.
pubmed: 2723121
Chertow GM, Seifter JL, Christiansen CL, O’Donnell WJ. Trimethoprim-sulfamethoxazole and hypouricemia. Clin Nephrol. 1996;46:193–8.
pubmed: 8879855
Bloch M, Gur E, Shalev AY. Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance? Psychopharmacology. 1992;109:377–8.
pubmed: 1365639
Perez-Gomez MV, Bartsch L-A, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential dangers of serum urate-lowering therapy. Am J Med. 2019;132:457–67.
pubmed: 30611833
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.
pubmed: 27457514